Cosmetic PDRN serum claims are an area where founders routinely get into trouble, because the ingredient's medical pedigree (it is used in injectable aesthetic medicine and wound-care products in South Korea and Europe) makes it tempting to borrow clinical language that crosses into drug-claim territory.
In the United States, the FDA regulates products as either cosmetics or drugs based on their intended use, not their ingredients. A PDRN serum sold with claims that it "heals wounds," "repairs damaged DNA," "stimulates collagen synthesis at the cellular level," or "regenerates skin tissue" is making drug claims and is subject to FDA drug regulations — which require premarket approval the vast majority of indie brands do not have. The same applies to language borrowed from injectable PDRN aesthetic medicine studies (e.g., "improves skin laxity through fibroblast activation").
Safe cosmetic claims for a PDRN serum in the US focus on appearance and sensory results: "visibly firms and smooths the look of skin," "skin appears more radiant and refreshed," "helps skin look more youthful," "visibly reduces the appearance of fine lines and uneven texture." Structure-function claims are the gray zone — "supports skin's natural renewal process" is arguably cosmetic, but "accelerates cellular renewal" starts to sound drug-like. When in doubt, add "appearance of" or "look of" and you move back toward safe cosmetic territory.
In the European Union, the EU Cosmetics Regulation (EC) No 1223/2009 governs claim standards and is supplemented by the Common Criteria for cosmetic claims (EU Regulation 655/2013). Claims must be truthful, substantiated by evidence in your PIF, fair (not denigrating competitors), and not attribute to the product characteristics it does not have. The EU also has specific guidance discouraging claims that imply a medical effect. The practical EU standard mirrors the US approach: appearance-based, experience-based claims supported by consumer testing or in vitro data are safe; therapeutic or cellular-mechanism claims are not.
For South Korea, where PDRN has a longer cosmetic history, claim standards are regulated by the MFDS and are somewhat more permissive around "functional cosmetic" designations — but if you are selling in Korea you must register the product accordingly and cannot simply re-use Korean marketing language on your US or EU packaging.
Best practice: build a claims matrix — a table listing each on-pack and digital claim, the regulatory basis for it, and the supporting evidence (in vitro study, consumer perception test, or ingredient supplier data) — before you go to print. Have a US regulatory consultant or EU safety assessor review it. The cost ($500–$2,000 for a claims review) is trivial compared to the cost of an FDA warning letter or an EU non-compliance notice.
Read the full guide on Private Label PDRN Salmon DNA Serum Manufacturer Low MOQ →